恩西地平诱导急性髓系白血病细胞分化以促进临床缓解
在复发/难治性IDH2突变急性髓系白血病中,恩西地平单药1期试验总缓解率为40.3%。本研究检测连续样本的2-HG、mIDH2等位基因负荷及共存体细胞突变,发现2-HG抑制先于临床缓解且不能单独预测缓解,NRAS等MAPK通路突变在无缓解患者中富集,支持分化是主要疗效机制。
要点
- 恩西地平在R140和R172两种mIDH2 AML亚型中均强效抑制2-HG,动力学不同且先于临床缓解。
- 2-HG抑制不能单独预测缓解,多数无缓解患者也出现2-HG抑制。
- NRAS及其他MAPK通路效应基因共存突变在无缓解患者中富集,RAS信号可能参与原发治疗抵抗。
核心结论
- 数据支持分化是恩西地平在复发/难治性AML患者中的主要疗效机制,并为耐药机制提供线索以指导未来基于机制的联合治疗研究。
研究设计与样本
- 基于恩西地平单药1期临床试验,检测连续患者样本的2-HG、mIDH2等位基因负荷及共存体细胞突变,并用流式细胞术评估mIDH2对造血分化的抑制。
主要发现
- 在R140和R172两种mIDH2 AML亚型中均观察到强效2-HG抑制,动力学不同且先于临床缓解。
- 2-HG抑制不能单独预测缓解,因为多数无缓解患者也出现2-HG抑制。
- 观察到完全缓解伴mIDH2持续存在,以及造血干/祖细胞区室正常化并出现功能性mIDH2中性粒细胞。
- 在部分完全缓解患者中,mIDH2等位基因负荷降低并随缓解保持不可测。
- NRAS及其他MAPK通路效应基因共存突变在无缓解患者中富集,与RAS信号参与原发治疗抵抗一致。
关键数值与推荐
- 恩西地平单药在1期试验中治疗mIDH2复发/难治性AML患者的总缓解率为40.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block. Single-agent enasidenib (AG-221/CC-90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a phase 1 trial. However, its mechanism of action and biomarkers associated with response remain unclear. Here, we measured 2-HG, mIDH2 allele burden, and co-occurring somatic mutations in sequential patient samples from the clinical trial and correlated these with clinical response. Furthermore, we used flow cytometry to assess inhibition of mIDH2 on hematopoietic differentiation. We observed potent 2-HG suppression in both R140 and R172 mIDH2 AML subtypes, with different kinetics, which preceded clinical response. Suppression of 2-HG alone did not predict response, because most nonresponding patients also exhibited 2-HG suppression. Complete remission (CR) with persistence of mIDH2 and normalization of hematopoietic stem and progenitor compartments with emergence of functional mIDH2 neutrophils were observed. In a subset of CR patients, mIDH2 allele burden was reduced and remained undetectable with response. Co-occurring mutations in NRAS and other MAPK pathway effectors were enriched in nonresponding patients, consistent with RAS signaling contributing to primary therapeutic resistance. Together, these data support differentiation as the main mechanism of enasidenib efficacy in relapsed/refractory AML patients and provide insight into resistance mechanisms to inform future mechanism-based combination treatment studies.
引用
- Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017. PMID: 28588019. doi:10.1182/blood-2017-04-779447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。